Brief: Jaguar Health Inc - Regains Compliance With Nasdaq S Bid Price Requirement
26/06/2024 13:53
June 26 (Reuters) - Jaguar Health Inc JAGX.O :
* REGAINS COMPLIANCE WITH NASDAQ S BID PRICE REQUIREMENT
* TO REPORT PIVOTAL PHASE 3 ONTARGET TRIAL RESULTS FOR ITS
CANCER
SUPPORTIVE CARE DRUG CROFELEMER ON OR BEFORE JULY 23
Source text for Eikon: ID:n0001104659-24-074995
Further company coverage: JAGX.O
((Reuters.Briefs@thomsonreuters.com;))